30results about How to "Suppress death" patented technology

The invention discloses a tissue preservation solution in organoid construction as well as a preparation method and application thereof. The tissue preservation solution is prepared from the following components: an Advanced DMEM / F12 culture medium, a mycillin / amphotericin B three-antibody mother solution, Glutamax-1, an HEPES buffer solution and a Y-27632 mother solution. The preparation method of the tissue preserving fluid comprises the following steps: adding an Advanced DMEM / F12 culture medium into a centrifugal tube on a super clean bench; then sequentially adding a mycillin / amphotericin B three-antibody mother solution, Glutamax-1, an HEPES buffer solution and Y-27632, and uniformly mixing, so as to obtain the tissue preservation solution. After uniformly mixing, filtering and sterilizing by using a disposable needle type filter, and collecting the preserving fluid into a centrifugal tube; the invention also discloses an application of the tissue preserving fluid in organoid construction. According to the tissue preserving fluid obtained by the invention, in the transportation process, the cell viability in the tissue is improved, the cell damage is reduced, and the success rate of primary cell adherent culture and organoid construction is increased.

The invention discloses a lactobacillus helveticus strain (Lactobacillus helveticus) and an application of the lactobacillus helveticus strain (Lactobacillus helveticus). The lactobacillus helveticus strain is named as C52, and the microbial preservation number of the lactobacillus helveticus strain is CGMCC (China General Microbiological Culture Collection Center) No. 30336. Researches show that the C52 strain has unique anti-inflammatory and anti-infection dual characteristics and also has the characteristics of acid resistance, cholate resistance and the like, and acute or chronic intestinal inflammation reaction caused by diarrhetic virus infection and diarrhea or death caused by the acute or chronic intestinal inflammation reaction can be inhibited only by oral administration of the C52 strain, so that the death rate is reduced. The novel lactobacillus helveticus strain C52 disclosed by the invention can be used as a probiotic strain to be added into feed and medicines, so that the anti-inflammatory and anti-infection capabilities of animals, especially the intestinal inflammation resistance and the intestinal infection resistance, are improved. The lactobacillus helveticus C52 strain with unique anti-inflammatory and anti-infection dual characteristics is expected to be used as an auxiliary treatment preparation for intestinal inflammation and infection, and particularly has a better protection effect when resisting and reducing intestinal acute inflammation, diarrhea and death caused by bacterial or virus infection.

The invention discloses application of 2-ME in preparation of a medicine for preventing or treating sepsis cardiomyopathy, low-dose 2-ME can recover the activity of myocardial cells damaged by sepsis, reduce the apoptosis rate of the myocardial cells and enhance the contractility of the myocardial cells, so that the heart function is improved; the 2-ME can significantly inhibit cell death, reduce accumulation of disulphide in cells and prevent occurrence of disulphide death, and has potential application prospects in myocardial protection and prevention and treatment of sepsis myocardial injury.

The invention belongs to the technical field of biological agents, and particularly relates to application of a TDP-43 inhibitor in preparation of a medicine for treating lung adenocarcinoma. Research results show that the TDP-43 can promote lung adenocarcinoma cell proliferation and inhibit cell death. By inhibiting the expression of the TDP-43, the proliferation activity of the cells can be remarkably reduced, and the cell death rate can be improved. In addition, the TDP-43 has the function of inhibiting ferroptosis of lung adenocarcinoma cells. After the TDP-43 is silenced, the expression of the iron ion chaperonin PCBP1 is obviously reduced. The TDP-43 can be used for positively regulating and controlling the expression level of the PCBP1.

The present invention relates to a 3-phenyl iso # imgabs0 # azole derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating ocular diseases containing the same as an active ingredient. The 3-phenyl iso # imgabs 1 # azole derivative or the pharmaceutically acceptable salt thereof of the present invention increases autophagy activity, thereby promoting removal of metabolic residues such as A2E accumulated in eyeballs, and effectively inhibiting eye cell damage or death caused by oxidation of A2E by blue light. Therefore, a pioneering therapeutic agent serving as a new concept can be provided for eye diseases such as dry macular degeneration without a fundamental treatment method at present.

The present invention relates to Regentide-034 and Regentide-041 and, more specifically, to a use of a mixture of Regentide-034 and Regentide-041 for improving skin conditions. A mixture of Regentide-034 and Regentide-041 according to the present invention is free of cytotoxicity and has remarkable effects of promoting cell proliferation and collagen synthesis, inhibiting elastase activity, and suppressing ultraviolet light-induced cell death and as such, can be variously utilized in the pharmaceutical, medicinal, cosmetic, and food fields.

The present invention relates to a triazole compound having a novel ring structure, a preparation method therefor, and a use thereof. The triazole compound having a novel ring structure according to the present invention exhibits excellent ASK1 inhibiting ability and inhibits apoptosis of neurons, and thus can be used for the prevention or treatment of ASK1-related diseases, including neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and liver diseases.

The present invention belongs to the technical field of pesticide preparations, and specifically relates to a pesticide composition for peanut white rot and a preparation method thereof, comprising three active ingredients, Fe2 (EDTA) 3-fluoxazolidinone nanocomposite, prothioconazole and azoxystrobin, wherein the mass ratio of the Fe2 (EDTA) 3-fluoxazolidinone nanocomposite, prothioconazole and azoxystrobin is 6-8:1:1. The pesticide composition for peanut white rot in the present invention is obtained by complexing EDTANa2 with iron ions to obtain Fe2 (EDTA) 3, which can be used as a synergist of fluoxazolidinone to improve the bactericidal effect of fluoxazolidinone, and on the other hand, iron also plays an important role in the electron transfer of the mitochondrial respiratory chain, and can synergistically enhance the bactericidal effect of fluoxazolidinone, so as to achieve a better bactericidal effect.

The invention discloses the application of pine pollen polysaccharide in preventing and treating atopic eczema, and belongs to the technical field of atopic eczema prevention and treatment. The pine pollen polysaccharide is prepared by the following method: adding broken wall masson pine pollen to petroleum ether, heating and refluxing extraction, collecting filter residue by suction filtration, drying and removing solvent, and obtaining defatted masson pine pollen; heating and refluxing extraction of defatted masson pine pollen with 95% ethanol, collecting filter residue by suction filtration, and drying and removing residual solvent to obtain impurity-removed masson pine pollen; adding water to the impurity-removed masson pine pollen, heating and boiling, repeatedly extracting and combining filtrates, heating and concentrating to obtain a concentrated solution; removing protein from the concentrated solution, precipitating with alcohol, centrifuging and precipitating, and freezing and decompressing to obtain pine pollen polysaccharide. Pine pollen polysaccharide is used to prevent and treat atopic eczema. Pine pollen polysaccharide comes from natural plants. Compared with traditional drugs, pine pollen polysaccharide has higher safety and lower side effects, and is particularly suitable for long-term use and sensitive populations such as infants and young children.

The invention relates to the technical field of medicines, in particular to application of a flavonoid metabolite for improving tacrolimus-induced chronic renal injury. The invention provides application of a flavonoid metabolite, namely quercetin-7-O-beta-glucuronide, in an abelmoschus esculentus capsule to improvement of chronic renal injury induced by tacrolimus, and particularly provides application of the flavonoid metabolite, namely quercetin-7-O-beta-glucuronide in the abelmoschus esculentus capsule. The research shows that the quincetin-7-O-beta-glucuronide has relatively strong biological activities of resisting inflammation, resisting oxidation, resisting fibrosis and the like, and plays an important role in preventing and treating the chronic renal injury caused by tacrolimus.

The invention discloses a preparation method of a cinnamyl aldehyde loaded silicon dioxide nano antibacterial agent, relates to a preparation method of a nano antibacterial agent, and aims to solve the technical problem that the antibacterial effect is influenced due to the fact that the conventional cinnamyl aldehyde antibacterial agent is easy to volatilize and poor in water solubility. The preparation method comprises the following steps: adding silicon dioxide into an alcohol solution of cinnamyl aldehyde, heating to boil, carrying out reflux reaction, and then centrifugally separating out a precipitate, thereby obtaining the cinnamyl aldehyde loaded silicon dioxide nano antibacterial agent. When the concentration of the nano-antibacterial agent is 0.4-1g / L, the diameter of an inhibition zone of the nano-antibacterial agent to staphylococcus aureus is about 30-55mm, and the diameter of an inhibition zone of the nano-antibacterial agent to escherichia coli is about 27-45mm. The method can be used in the field of antibacterial agents.

The invention discloses application of pine pollen polysaccharide in prevention and treatment of atopic eczema, and belongs to the technical field of atopic eczema prevention and treatment. The pine pollen polysaccharide is prepared by the following method: adding wall-broken masson pine pollen into petroleum ether, performing heating reflux extraction, performing suction filtration to collect filter residues, and drying to remove a solvent to obtain degreased masson pine pollen; heating, refluxing and extracting the degreased pinus massoniana pollen by using 95% ethanol, carrying out suction filtration, collecting filter residues, and drying to remove a residual solvent, so as to obtain impurity-removed pinus massoniana pollen; adding water into the impurity-removed masson pine pollen, heating and boiling, repeatedly extracting, combining filtrate, and heating and concentrating to obtain a concentrated solution; and removing protein from the concentrated solution, and carrying out alcohol precipitation, centrifugal separation and precipitation, freezing and drying under reduced pressure to obtain the pollen pini polysaccharide. The pine pollen polysaccharide is used for preventing and treating the atopic eczema, the pine pollen polysaccharide is derived from natural plants, and compared with traditional medicines, the pine pollen polysaccharide has higher safety and lower side effects and is particularly suitable for sensitive people such as infants and the like after being used for a long time.

The invention provides a preparation method and application of broad-spectrum anti-tumor nano-liposome, and the preparation method comprises the following steps: dissolving 15mg of ginsenoside Rg3 and 50mg of PL-100M in 10ml of absolute ethyl alcohol together, then transferring into an eggplant-shaped bottle, and carrying out reduced pressure rotary evaporation until a solvent is volatilized and a uniform film is visible on the bottle wall; the preparation method comprises the following steps: dissolving 5mg of cysteine and 0.5 g of glucose in 10ml of pure water, adding an aqueous solution into an eggplant-shaped bottle, and carrying out ultrasonic hydration until a film completely falls off to obtain a lipidosome crude suspension; and carrying out ultrasonic treatment on the suspension for 30 times under 270W by using a probe ultrasonic instrument to form the Rg3-Lp / Cysteine liposome. The novel cell death type, namely disulfur death, is targeted to tumor metabolism, the target spot is GLUT1 which is generally and highly expressed on the surfaces of tumor cells, and the anti-tumor effect of the nano-liposome has broad spectrum and has no influence on normal tissues.

The application relates to a hydrogel for regulating a cGAS-STING path by mitochondria autophagy and a preparation method and application thereof, the preparation method comprising the following steps: preparation of spirulina loaded with deferoxamine and preparation of the hydrogel; the drug-loaded hydrogel system of the application has the functions of wet tissue adhesion and multi-dimensional pathological microenvironment regulation, fully utilizes the effects of the components, realizes regulation of cell fate from a molecular level, induces macrophages to polarize into M2 type, targets inhibition of a cGAS-STING path and ferroptosis, and remolds an immune microenvironment of a wound surface, thereby providing a new strategy and idea for repair of a burn infection wound surface.

This application discloses the use of USP15 inhibitors in the preparation of medicaments for the treatment and / or prevention of renal cell carcinoma, as well as pharmaceutical compositions and kits thereof.

The invention relates to new application of melatonin in prevention and treatment of potato dry rot and a plant fungicide for prevention and treatment of potato dry rot, and belongs to the technical field of potato disease prevention and treatment. In order to solve the problems that pathogenic bacteria easily generate resistance and seriously pollute the environment due to long-term use of the existing bactericide, the invention provides a new application of melatonin in prevention and treatment of potato dry rot and a plant bactericide for prevention and treatment of potato dry rot. Experiments prove that the exogenous melatonin can inhibit mycelial growth and spore germination of potato dry rot pathogenic bacteria fusarium oxysporum, and can inhibit the activity of fusarium oxysporum CAT, POD, SOD and GR to cause thallus death by destroying the cell membrane of fusarium oxysporum, so as to control the disease development of the dry rot. The fusarium oxysporum is treated by exogenous application of melatonin, growth and development of the fusarium oxysporum can be obviously inhibited, and a new way is provided for prevention and treatment of potato dry rot.

The invention discloses application of corydalis saxicola in preparation of a medicine for preventing and treating liver microcirculation disturbance or liver injury caused by lipopolysaccharide. When lipopolysaccharide induction is carried out or 6 hours after lipopolysaccharide induction is carried out; corydalis saxicola bunting injection with corydalis saxicola bunting alkali as active ingredient for intravenous or intramuscular injection, which can reduce the number of leukocytes rolling and adhering to the central vein region of the liver, the level of serum alanine transaminase (ALT) and aspartate transaminase (AST), the necrosis area of the liver tissue, the tumor necrosis factor-alpha (TNF-alpha) of the liver tissue and interferon-gamma (IFN-gamma) of the liver tissue, wherein the number of leukocytes rolling and adhering to the central vein region of the liver is increased due to lipopolysaccharide increase. And content.

The invention discloses a phytophthora pini effector protein PpinAvh23 as well as a coding gene and application thereof, and belongs to the technical field of molecular biology. The amino acid sequence of the protein is as shown in SEQ ID NO. 1. Experiments show that the protein can specifically inhibit programmed death of plant cells induced by pathogenic bacteria elicitors, and it is proved that the protein can promote pathogen infection as a toxic effector in plants. The invention also provides a gene (SEQ ID NO.2) for coding the protein. The protein and the coding gene thereof can be used as a key molecular tool and a screening target for researching a plant-pathogen interaction mechanism, and a basis is provided for developing a new strategy for preventing and controlling plant diseases.

This application provides a biomimetic mineralized hydrogel, relating to the field of medical polymer materials. The biomimetic mineralized hydrogel provided in this application uses a biodegradable polymer containing carboxylate groups as a mineralization template, and phosphate-containing small molecules as strong ligands and phosphate donors, inducing Fe... 3+ In-situ mineralization forms stable iron-bearing mineralized crystals, achieving Fe³⁺ + Long-term, low-dose sustained release, thereby delivering Fe 3+ The concentration is maintained within a safe window to allow it to exert its positive bioregulatory effects while avoiding the risks of iron overload-induced oxidative damage and ferroptosis. Simultaneously, it slows the release of Fe³⁺. + It can regulate cellular iron metabolism and activate antioxidant stress-related pathways, inhibit ferroptosis, and create a favorable repair microenvironment for osteochondral regeneration. Experimental results show that this hydrogel not only has excellent flexibility, biocompatibility, antibacterial properties, and angiogenesis-promoting properties, but also promotes osteogenic and chondrogenic differentiation of cells, thereby achieving an integrated osteochondral repair effect.

This invention belongs to the field of targeted drug technology, and specifically relates to the application of PRDX3 protein as a drug target in screening drugs for the prevention and / or treatment of COPD induced by cigarette smoke. This invention demonstrates that the expression level of PRDX3 protein is increased in COPD mouse models and in cigarette smoke-induced MLE-12 alveolar epithelial cells, and also explores the effect of PRDX3 on COPD disease progression. Overexpression of PRDX3 in alveolar epithelial cells significantly improves lung function and lung tissue damage in COPD mice, while knockdown of PRDX3 exacerbates COPD symptoms in COPD mice. This invention provides a novel drug target and candidate compound for the treatment of COPD, and has significant clinical application value.

The invention discloses a titanium dioxide-molybdenum disulfide ultrasonic triggering antibacterial coating and a preparation method and application thereof.The preparation method comprises the following steps that a titanium sheet serves as a working electrode, the working electrode, a counter electrode and electrolyte form an electrochemical anodic oxidation system, electrochemical anodic oxidation is conducted for 5-60 min under 10-50 V, and the titanium sheet loaded with titanium dioxide nanotubes is obtained; in a nitrogen or inert gas atmosphere, the titanium sheet loaded with the titanium dioxide nanotube is subjected to heat preservation at 400-500 DEG C for 0.5-1 h and cooled to the room temperature, and a first substance is obtained; and molybdenum disulfide is used as a target material, the first substance is subjected to magnetron sputtering for 0.5-4 min in the inert gas atmosphere, and the titanium dioxide-molybdenum disulfide ultrasonic triggering antibacterial coating is obtained on a titanium sheet. The titanium dioxide-molybdenum disulfide ultrasonic triggering antibacterial coating disclosed by the invention can generate heat and active oxygen under the triggering of ultrasonic waves, and can inhibit bacterial growth and cause bacterial death through the comprehensive action of the active oxygen and the heat, so that the antibacterial effect is improved.

The present invention relates to naphthopyrone derivatives and compositions containing Cassia seed bud extracts containing the same as active ingredients. The composition according to one aspect of the present invention has an antioxidant effect, and an effect of protecting nerve cells from oxidative stress or inhibiting nerve cell death, and in particular, has an effect of inhibiting damage or death of retinal nerve cells or hippocampal nerve cells caused by glutamate toxicity, and can be used as a pharmaceutical composition for the treatment or prevention of decreased vision and eye diseases caused by optic nerve damage, and memory loss, learning impairment, depression onset and deterioration, and degenerative brain nerve diseases caused by cranial nerve damage.

The invention belongs to the field of medical technology, and specifically relates to a prescription for treating ulcerative colitis and its application. The prescription comprises rhododendron australis, cardamom and galangal. The prescription and the prescription extract and medicine based on the prescription can effectively restore the intestinal length of the body, protect the integrity of the intestinal barrier of the body, regulate the imbalance of the intestinal acid-base homeostasis of the body, inhibit the death of intestinal epithelial cells of the body and reduce the level of ROS in the intestinal tract of the body, thereby achieving the purpose of treating ulcerative colitis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of an exogenous recombinant protein ANXA5 in preparation of a medicine for treating cerebral hemorrhage. The invention reveals that the expression level of ANXA5 after cerebral hemorrhage is increased; by adding the recombinant ANXA5 protein, the expression level of ferroptosis related protein can be reduced; meanwhile, the expression level of apoptotic protein is reversed, the oxidative stress level is reduced, and the MDA and active oxygen levels are obviously reduced, which proves that the recombinant protein ANXA5 plays an inhibiting role in neuronal ferroptosis after cerebral hemorrhage. The invention provides a basis for using the recombinant protein ANXA5 as a novel medicine for treating cerebral hemorrhage, especially ferroptosis caused by cerebral hemorrhage.

The invention provides application of an APEX1 gene in preparation of a medicine for preventing or treating Parkinson's disease, and belongs to the technical field of biomedicine.The APEX1 can be combined with Nrf2 to promote expression of a downstream antioxidant element ARE, so that active oxygen accumulation induced by mitochondrial membrane potential change is resisted, and then dopaminergic neuron death is inhibited. The APEX1 gene is applied to preparation of a medicine for preventing and treating the Parkinson's disease, and the Parkinson's disease is expected to be fundamentally improved or treated.

This invention relates to the field of composite fiber technology, specifically to a graphene-modified polyamide 6 composite fiber and its preparation method. The composite fiber of this application is obtained by adding chlorinated modified graphene to polyamide 6, followed by compounding and molding. The preparation method of the chlorinated modified graphene includes the following steps: coating graphene oxide with silica; subjecting the silica-coated graphene oxide to acylchlorination treatment, then grafting L-glutamic acid; modifying the grafted graphene with 5,5-dimethyl-3-(3'-triethoxysilylpropyl)hydantoin to obtain modified graphene; and chlorinating the modified graphene with sodium hypochlorite to obtain chlorinated modified graphene. The composite fiber of this application has advantages such as high tensile strength and good antibacterial effect.

The invention relates to an application of valine-restricted diet or a combination of valine-restricted diet and a poly ADP-ribose polymerase inhibitor in preparation of drugs for preventing and / or treating tumors, especially in prevention and treatment of colorectal cancer, and has the advantages that the valine-restricted diet can induce cells to generate DNA damage, so that the effect of preventing and treating colorectal cancer is achieved. Limiting the amount of valine in food has an obvious inhibiting effect on occurrence and development of tumors. The poly ADP-ribose polymerase inhibitor for blocking DNA damage repair by combining the valine restricted diet and the poly ADP-ribose polymerase inhibitor can block or inhibit DNA damage repair and more effectively inhibit DNA damage repair, so that cell proliferation is inhibited, cell death is promoted, and occurrence and development of tumors are further inhibited.

The application belongs to the field of clinical drug toxic side effects, and particularly relates to the use of phenazine-1-carboxylic acid in treating cisplatin-mediated acute kidney injury. The application first discovers and proves that phenazine-1-carboxylic acid can effectively alleviate cisplatin-induced acute kidney injury. In a cisplatin-induced acute kidney injury model of mice, intraperitoneal injection of phenazine-1-carboxylic acid can effectively protect kidney function, which is specifically manifested as follows: significantly reducing urea nitrogen and creatinine levels in serum of model mice; reducing pathological injury of kidney tissue and reducing tubular injury score; and inhibiting expression of inflammatory factors and injury markers in kidney tissue. The treatment effect is equivalent to that of a classic ferroptosis inhibitor, Ferrostatin-1, and a new candidate drug for solving the dose-limiting toxicity of cisplatin in clinical application is provided.

The invention relates to the technical field of films, and discloses an antibacterial PE film and a preparation method thereof. The PE film prepared by the invention comprises the following raw materials in parts by weight: 35-45 parts of low-density polyethylene, 15-25 parts of high-density polyethylene, 10-20 parts of metallocene linear low-density polyethylene, 5-10 parts of maleic anhydride grafted POE, 5-10 parts of a composite antibacterial agent, 2-5 parts of a lubricant and 1-3 parts of an antioxidant. The PE film not only has the barrier property of the traditional PE film, but also is endowed with excellent antibacterial property by adding the composite antibacterial agent.

The invention relates to a rigid-flexible composite nerve conduit capable of controllably delivering anti-inflammatory substances, which comprises a polymer fiber conduit part and a hydrogel part, and the polymer fiber conduit part is a conduit prepared from a double-layer polymer fiber membrane of which the inner layer is unidirectionally ordered and the outer layer is irregularly arranged; and the hydrogel part is a modified biological macromolecular hydrogel containing anti-inflammatory substance nanoparticles. According to the invention, low-modulus hydrogel with an adjustable degradation rate is used as a carrier of drug-loaded nanoparticles and is combined with an electrostatic spinning nanofiber scaffold which is similar to an extracellular matrix structure and has excellent mechanical properties to form an ideal design of the rigid-flexible composite nerve conduit capable of controllably delivering anti-inflammatory substances; due to the existence of the hydrogel, in-situ controllable delivery of the drug-loaded nanoparticles can be realized, the action efficiency of the nanoparticles is improved, the electrostatic spinning nanofiber with an adjustable topological structure can stabilize the form of the hydrogel, and the hydrogel plays a guiding and promoting role in subsequent spinal cord total transection injury repair after being degraded.